NCT00317486 – A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Posted on August 28, 2025 by Molly Willeford -
A double-blind, randomized, placebo-controlled study to assess the effect of Tracleer™ (bosentan) in combination with the initiation of epoprostenol therapy on cardiopulmonary hemodynamics in patients with severe pulmonary arterial hypertension Posted on August 28, 2025 by Molly Willeford -
NCT00367770 – A Multi-Center, Open-Label Extension Study to Protocol AC-052-405 to Evaluate the Safety and Efficacy of Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology Posted on August 28, 2025 by Molly Willeford -
NCT00319696 – Long-term Bosentan Open Label Extension of the AC-052-331 Study in Systemic Sclerosis Patients With Ischemic Digital Ulcers Posted on December 5, 2019 by tsuperadmin -
NCT01338415 – A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension Posted on December 5, 2019 by tsuperadmin -
NCT01223352 – An Open-label, Prospective Multicenter Study to Assess the Pharmacokinetics, Tolerability, Safety and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension Posted on December 5, 2019 by tsuperadmin -
NCT00319020 – An Open Label, Long-term, Safety, and Tolerability Extension Study Using the Pediatric Formulation of Bosentan in the Treatment of Children With Idiopathic or Familial Pulmonary Arterial Hypertension Who Completed FUTURE 1 Posted on December 5, 2019 by tsuperadmin -
NCT00313222 – Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Posted on December 5, 2019 by tsuperadmin -
NCT00319267 – An Open Label, Multicenter Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Pediatric Formulation of Bosentan in Children With Idiopathic or Familial Pulmonary Arterial Hypertension Posted on December 5, 2019 by tsuperadmin -
NCT00319033 – Long-term Open-label Study in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis Who Completed the Protocol AC-052-330 Posted on November 27, 2019 by tsuperadmin -
The YODA Project